Citius Pharmaceuticals (CTXR) Competitors $3.30 +0.04 (+1.23%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CTXR vs. TARA, INZY, MGX, IGMS, MIST, OSTX, ENTA, DBVT, CRDL, and ELUTShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Protara Therapeutics (TARA), Inozyme Pharma (INZY), Metagenomi (MGX), IGM Biosciences (IGMS), Milestone Pharmaceuticals (MIST), OS Therapies (OSTX), Enanta Pharmaceuticals (ENTA), DBV Technologies (DBVT), Cardiol Therapeutics (CRDL), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Protara Therapeutics Inozyme Pharma Metagenomi IGM Biosciences Milestone Pharmaceuticals OS Therapies Enanta Pharmaceuticals DBV Technologies Cardiol Therapeutics Elutia Citius Pharmaceuticals (NASDAQ:CTXR) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends. Do analysts rate CTXR or TARA? Citius Pharmaceuticals presently has a consensus price target of $54.50, suggesting a potential upside of 1,551.52%. Protara Therapeutics has a consensus price target of $22.67, suggesting a potential upside of 398.17%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than Protara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CTXR or TARA? Citius Pharmaceuticals received 175 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Protara Therapeutics an outperform vote while only 62.43% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCitius PharmaceuticalsOutperform Votes21162.43% Underperform Votes12737.57% Protara TherapeuticsOutperform Votes3666.67% Underperform Votes1833.33% Do insiders & institutionals have more ownership in CTXR or TARA? 16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 15.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, CTXR or TARA? Citius Pharmaceuticals has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Which has better earnings and valuation, CTXR or TARA? Protara Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14M-$6.00-0.55Protara TherapeuticsN/AN/A-$40.42M-$2.82-1.61 Does the media refer more to CTXR or TARA? In the previous week, Protara Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for Protara Therapeutics and 1 mentions for Citius Pharmaceuticals. Protara Therapeutics' average media sentiment score of 0.47 beat Citius Pharmaceuticals' score of 0.27 indicating that Protara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Citius Pharmaceuticals Neutral Protara Therapeutics Neutral Is CTXR or TARA more profitable? Citius Pharmaceuticals' return on equity of -48.42% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -48.42% -39.24% Protara Therapeutics N/A -55.96%-49.06% SummaryCitius Pharmaceuticals beats Protara Therapeutics on 9 of the 16 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.05M$6.36B$5.24B$8.95BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-0.559.7889.3017.34Price / SalesN/A315.001,255.2478.66Price / CashN/A61.4443.8235.97Price / Book0.326.055.324.79Net Income-$39.14M$154.90M$122.69M$225.00M7 Day Performance-9.09%-1.70%-0.16%1.52%1 Month Performance27.41%2.72%3.75%4.68%1 Year Performance-82.40%2.83%27.41%20.89% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.8492 of 5 stars$3.30+1.2%$54.50+1,551.5%-82.7%$28.05MN/A-0.5520Short Interest ↑TARAProtara Therapeutics3.2229 of 5 stars$5.24-5.8%$22.67+332.6%+105.9%$108.10MN/A-1.8630INZYInozyme Pharma3.4684 of 5 stars$1.68-16.0%$18.33+991.3%-68.0%$107.92MN/A-1.0850Short Interest ↑MGXMetagenomi1.6478 of 5 stars$2.88-8.0%$16.67+478.7%N/A$107.78M$55.08M0.00236Short Interest ↑News CoveragePositive NewsGap DownIGMSIGM Biosciences4.6875 of 5 stars$1.81-13.4%$5.50+203.9%-82.2%$107.63M$2.92M-0.50190Gap UpMISTMilestone Pharmaceuticals3.1281 of 5 stars$1.98-4.8%$13.00+556.6%+32.0%$105.59M$1M-2.4430Positive NewsOSTXOS Therapies2.1687 of 5 stars$4.86-2.2%$8.00+64.6%N/A$104.65MN/A0.00N/AAnalyst ForecastInsider TradeNews CoverageENTAEnanta Pharmaceuticals4.5015 of 5 stars$4.89-3.9%$17.25+252.8%-55.8%$103.64M$67.64M-0.89160DBVTDBV Technologies3.8693 of 5 stars$5.02+1.0%$22.50+348.2%-48.0%$103.26M$15.73M-1.1280Analyst ForecastShort Interest ↓Gap DownCRDLCardiol Therapeutics2.4782 of 5 stars$1.25-2.3%$8.75+600.0%+18.6%$102.13M$60,000.00-3.2120Positive NewsELUTElutia3.0805 of 5 stars$2.93-10.1%$10.00+241.3%-3.6%$101.27M$24.78M-1.12180Positive NewsGap Down Related Companies and Tools Related Companies TARA Competitors INZY Competitors MGX Competitors IGMS Competitors MIST Competitors OSTX Competitors ENTA Competitors DBVT Competitors CRDL Competitors ELUT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTXR) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTXR Stock Alerts